Abstract
The circulating variants of SARS-CoV-2 pose a threat to the public health response worldwide, especially in the case of developing countries, lacking vaccines and having compromised health-care facilities. This article highlights several recent studies conducted to determine the efficacy of COVID-19 vaccines against variants of concern. These studies comprise clinical trials and neutralization assay-based studies conducted on messenger RNA (mRNA), recombinant, viral vector-based, and inactivated vaccines.